Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
69,342.35 +1,612.77 (+2.38%) CMC Crypto 200
1,400.57 +69.97 (+5.26%)
Beam Therapeutics Inc. (BEAM)
After hours:
| Previous close | 32.17 |
| Open | 32.72 |
| Bid | 33.11 x 300 |
| Ask | 33.20 x 300 |
| Day's range | 32.35 - 34.09 |
| 52-week range | 16.95 - 49.50 |
| Volume | |
| Avg. volume | 1,336,464 |
| Market cap | 2.728B |
| Beta (5Y monthly) | 1.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.60 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 50.46 |
ZacksBeam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
Beam Therapeutics (BEAM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ZacksBeam Therapeutics' (BEAM) CFO to Step Down, Stock Declines
Beam Therapeutics' (BEAM) current chief financial officer, Terry-Ann Burrell, is set to step down from her role on Aug 9. The stock falls 4.7%.
GlobeNewswireBeam Therapeutics Announces Transition of Chief Financial Officer
CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase. As part of a transition process, the company has initiated a search for a successor. “Terry-Ann has been an invaluab
